首页> 美国卫生研究院文献>other >De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

【2h】

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

机译：从头ALK激酶结构域突变在未使用激酶抑制剂的ALK重排肺癌中并不常见

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionAnaplastic lymphoma kinase (ALK) rearranged lung adenocarcinomas are responsive to the multitargeted ALK inhibitor crizotinib. One of the common mechanisms of resistance to crizotinib is the acquisition of ALK kinase domain mutations. However, the presence of ALK mutations in crizotinib-naïve tumors has not been widely reported and it is unclear if de novo ALK mutations affect the response to crizotinib.

机译：简介再生障碍性淋巴瘤激酶（ALK）重排的肺腺癌对多靶点ALK抑制剂克唑替尼有反应。克唑替尼耐药的常见机制之一是获得ALK激酶结构域突变。然而，未曾有过克唑替尼的肿瘤中ALK突变的存在尚未得到广泛报道，也不清楚从头ALK突变是否影响对克唑替尼的反应。

著录项

期刊名称 other
作者
Antonio R. Lucena-Araujo; Jason P. Moran; Paul A. VanderLaan; Dora Dias-Santagata; Erik Folch; Adnan Majid; Michael S. Kent; Sidharta P. Gangadharan; Deepa Rangachari; Mark S. Huberman; Susumu S. Kobayashi; Daniel B. Costa;
展开▼
作者单位

展开▼
年(卷),期 -1(99),-1
年度 -1
页码 17–22
总页数 12
原文格式 PDF
正文语种
中图分类
关键词
mutation lung cancer adenocarcinoma ALK kinase domain crizotinib;

机译：突变;肺癌;腺癌;ALK;激酶结构域;克唑替尼;

相似文献

外文文献
中文文献
专利

1. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naive ALK rearranged lung cancers [J] . Lucena-Araujo Antonio R., Moran Jason P., VanderLaan Paul A., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：从头开始的ALK激酶结构域突变在未使用激酶抑制剂的ALK重排肺癌中并不常见
2. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naive ALK rearranged lung cancers [J] . Lucena-Araujo Antonio R., Moran Jason P., VanderLaan Paul A., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：在激酶抑制剂 - 野alk重新排列的肺癌中，De Novo Alk激酶结构域突变是罕见的
3. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK -rearranged non–small–cell lung cancer harbored coexisting EGFR mutation [J] . Akihiko Miyanaga, Kumi Shimizu, Rintaro Noro, BMC Cancer . 2013,第1期

机译：EGFR酪氨酸激酶和ALK抑制剂对EML4–ALK重排的非小细胞肺癌具有EGFR突变的活性
4. Activin receptor like kinase-1 (Alk-1) and soluble type I TGF-? receptor (Sol RI) are expressed and they regulate TGF-? responses in human chondrocytes [C] . W. Parker, M. Choi, A. Philip Annual meeting of the Society For Biomaterials . 2003

机译：激活素受体，如激酶-1（Alk-1）和可溶性I型TGF-β受体（Sol RI）表达并调节TGF-β。人软骨细胞的反应
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1 multicentre open-label ASCEND-1 trial [O] . Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, -1

机译：ceritinib对未接受过ALK抑制剂治疗和先前接受过ALK抑制剂治疗的ALK重排非小细胞肺癌（NSCLC）患者的颅内和全身反应：第一阶段多中心开放标签ASCEND-1的最新结果试用
7. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers [O] . Antonio R. Lucena-Araujo, Jason P. Moran, Paul A. VanderLaan, 2016

机译：在激酶抑制剂-Naïveak-naïveak重新排列的肺癌中，De Novo Alk激酶结构域突变罕见

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

摘要

著录项

相似文献

相关主题

期刊订阅